Deyao Li

Deyao Li

Auto-generated profile, based on publicly available information

Deyao Li

Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ADAdam David Durbin
Adam David Durbin
TWTingjian Wang
Tingjian Wang
VWVirangika K. Wimalasena
Virangika K. Wimalasena
MZMark W. Zimmerman
Mark W. Zimmerman
DLDeyao Li
Deyao Li
JQJun Qi
Jun Qi
Gene expression is regulated by promoters and enhancers marked by histone H3 lysine 27 acetylation (H3K27ac), which is established by the paralogous histone acetyltransferases (HAT) EP300 and CBP. These enzymes display overlapping regulatory roles in untransformed cells, but less characterized roles in cancer cells. We demonstrate that the majority of high-risk pediatric neuroblastoma (NB) depends on EP300, whereas CBP has a limited role. EP300 controls enhancer acetylation by interacting with TFAP2β, a transcription factor member of the lineage-defining transcriptional core regulatory circuitry (CRC) in NB. To disrupt EP300, we developed a proteolysis-targeting chimera (PROTAC) compound termed “JQAD1” that selectively targets EP300 for degradation. JQAD1 treatment causes loss of H3K27ac at CRC enhancers and rapid NB apoptosis, with limited toxicity to untransformed cells where CBP may compensate. Furthermore, JQAD1 activity is critically determined by cereblon (CRBN) expression across NB cells. Significance: EP300, but not CBP, controls oncogenic CRC-driven transcription in high-risk NB by binding TFAP2β. We developed JQAD1, a CRBN-dependent PROTAC degrader with preferential activity against EP300 and demonstrated its activity in NB. JQAD1 has limited toxicity to untransformed cells and is effective in vivo in a CRBN-dependent manner. This article is highlighted in the In This Issue feature, p. 587

28 October 2022 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
EPEshini Panditharatna
Eshini Panditharatna
JMJoana G. Marques
Joana G. Marques
TWTingjian Wang
Tingjian Wang
MTMaria C. Trissal
Maria C. Trissal
ILIlon Liu
Ilon Liu
MFMariella G. Filbin
Mariella G. Filbin
Diffuse midline gliomas are uniformly fatal pediatric central nervous system cancers that are refractory to standard-of-care therapeutic modalities. The primary genetic drivers are a set of recurrent amino acid substitutions in genes encoding histone H3 (H3K27M), which are currently undruggable. These H3K27M oncohistones perturb normal chromatin architecture, resulting in an aberrant epigenetic landscape. To interrogate for epigenetic dependencies, we performed a CRISPR screen and show that patient-derived H3K27M-glioma neurospheres are dependent on core components of the mammalian BAF (SWI/SNF) chromatin remodeling complex. The BAF complex maintains glioma stem cells in a cycling, oligodendrocyte precursor cell–like state, in which genetic perturbation of the BAF catalytic subunit SMARCA4 (BRG1), as well as pharmacologic suppression, opposes proliferation, promotes progression of differentiation along the astrocytic lineage, and improves overall survival of patient-derived xenograft models. In summary, we demonstrate that therapeutic inhibition of the BAF complex has translational potential for children with H3K27M gliomas. Significance: Epigenetic dysregulation is at the core of H3K27M-glioma tumorigenesis. Here, we identify the BRG1–BAF complex as a critical regulator of enhancer and transcription factor landscapes, which maintain H3K27M glioma in their progenitor state, precluding glial differentiation, and establish pharmacologic targeting of the BAF complex as a novel treatment strategy for pediatric H3K27M glioma. See related commentary by Beytagh and Weiss, p. 2730. See related article by Mo et al., p. 2906. This article is highlighted in the In This Issue feature, p. 2711

26 May 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JMJ. Justin Milner
J. Justin Milner
CTClara Toma
Clara Toma
SQSara Quon
Sara Quon
KOKyla Omilusik
Kyla Omilusik
NSNicole Scharping
Nicole Scharping
AGAnanda W. Goldrath
Ananda W. Goldrath
In response to infection, pathogen-specific CD8 T cells differentiate into functionally diverse effector and memory T cell populations critical for resolving disease and providing durable immunity. Through small-molecule inhibition, RNAi studies, and induced genetic deletion, we reveal an essential role for the chromatin modifier and BET family member BRD4 in supporting the differentiation and maintenance of terminally fated effector CD8 T cells during infection. BRD4 bound diverse regulatory regions critical to effector T cell differentiation and controlled transcriptional activity of terminal effector–specific super-enhancers in vivo. Consequentially, induced deletion of Brd4 or small molecule–mediated BET inhibition impaired maintenance of a terminal effector T cell phenotype. BRD4 was also required for terminal differentiation of CD8 T cells in the tumor microenvironment in murine models, which we show has implications for immunotherapies. Taken together, these data reveal an unappreciated requirement for BRD4 in coordinating activity of cis regulatory elements to control CD8 T cell fate and lineage stability.

1 May 2013 in Journal of Crystal Growth
Verified
Journal Article
Closed access
KZKun Zhou
Kun Zhou
JLJianping Liu
Jianping Liu
SZShuming Zhang
Shuming Zhang
ZLZengcheng Li
Zengcheng Li
Meixin FengMeixin Feng
Meixin Feng
Hui YangHui Yang
Hui Yang

12 April 2019 in Japanese Journal of Applied Physics
Verified
Journal Article
Closed access
PDF file
MIMasao Ikeda
Masao Ikeda
FZFeng Zhang
Feng Zhang
RZRenlin Zhou
Renlin Zhou
JLJianping Liu
Jianping Liu
SZShuming Zhang
Shuming Zhang
Hui YangHui Yang
Hui Yang
The room temperature photoluminescence (PL) intensity of In x Ga 1- x N/In y Ga 1- y N multiple quantum wells were correlated with the structural properties such as polarization strength and ground-state quantum levels for the triangular quantum wells. For x – y ≤ 0.2, the PL intensity increased with increasing the In-content of the well. In this region, we found that the PL intensity can be well described by the thermionic emission process with an activation energy corresponding to the energy difference between the valence band of barrier and the quantum level of holes in the well at the well/barrier interface. The pre-factor of the exponential component of effective barrier, reflecting the effective density of nonradiative recombination centers in the barriers, was 3.7 times larger for the samples with GaN barriers than that with InGaN barriers, indicating that the PL intensity is also influenced by the optical quality of barriers when the effective barrier height is relatively low.

1 October 2009 in Journal of Magnetism and Magnetic Materials
Verified
Journal Article
Closed access
Wei WangWei Wang
Wei Wang
DLDeyao Li
Deyao Li